赛克赛斯启动上市辅导 深耕医用生物材料领域

Core Viewpoint - Sykes Bio-Tech Co., Ltd. (referred to as "Sykes") has resumed its application for an A-share listing, with guidance from Everbright Securities, after previously withdrawing its IPO application in January 2025 due to market conditions and strategic considerations [1] Group 1: Company Overview - Sykes is a high-tech enterprise specializing in the research, production, and sales of implantable biomaterials for medical devices, focusing on areas such as hemostasis, surgical adhesion prevention, tissue sealing, and interventional embolization [1] - The company currently has 20 medical device products, including 8 Class III medical devices, with 3 being exclusive domestic products [1] Group 2: Product Performance - Key products include surgical adhesion prevention liquid, composite microporous polysaccharide hemostatic powder, absorbable dura mater sealing medical glue, and absorbable vascular sealing medical glue, with the first two having over 10 years of clinical application and a market acceptance rate above 26% [2] - As of the date of the prospectus, the absorbable dura mater sealing medical glue holds the top market share, while the absorbable vascular sealing medical glue is the only domestic brand in its category [2] - From 2021 to 2023, the sales volume of absorbable dura mater sealing medical glue and absorbable vascular sealing medical glue grew rapidly, with compound annual growth rates of 43.36% and 118.93%, respectively [2] Group 3: Financial Performance - Sykes reported revenues of 437 million yuan, 436 million yuan, and 379 million yuan for the years 2021, 2022, and 2023, respectively, with net profits of 127 million yuan, 137 million yuan, and 150 million yuan during the same period [2] Group 4: Fundraising and Future Plans - The company plans to raise 455 million yuan through its IPO to invest in the second phase of its biopharmaceutical production and research base, as well as for development reserve funds [3] - The second phase project aims to establish a biopharmaceutical production and research base focused on the development of research projects, with part of the raised funds allocated for R&D investment [3] - The controlling shareholder of Sykes is Shandong Saixing Holding Group Co., Ltd., which holds 72.11% of the company's shares [3]